Professor Gregory Gregoriadis PhD, DSc
Chief Scientific Officer
Professor Gregory Gregoriadis is Lipoxen's Chief Scientific Officer. In 1997 he founded Lipoxen as a spin out from The School of Pharmacy, University of London, where he was Head of the Centre for Drug Delivery Research (1990-2001). Prior to this, he was Head of The Liposomal Therapeutics Group at the Medical Research Council.
Gregory is an internationally acknowledged expert in drug and vaccine delivery. In 1971 he was the first to introduce the use of liposomes as a drug and vaccine delivery and in 1991 he introduced the use of polysialic acid as a means to improve the pharmacological action of peptide and protein drugs. He has published nearly 400 research papers, reviews and articles, as well as 27 volumes on drug delivery and targeting. His achievements have been honoured with the Controlled Release Society Founders Award (1994), the A.D. Bangham FRS Life Achievement Award (1995), his election as a Fellow of the American Association of Pharmaceutical Scientists (1998), a DSc from the University of London (2001) and The Journal of Drug Targeting Life Achievement Award (2008) all for exceptional contributions to the field of drug and vaccine delivery.
Gregory's seminal contributions to the field of drug and vaccine delivery are also reflected in his founding in 1978 of the ongoing Gordon Research Conference series 'Drug Carriers in Medicine and Biology', his directorships of the NATO Advanced Studies Institute's 'Targeting of Drugs' and 'Vaccines' (1981-1999), his Chairmanship of the 'Liposome Advances' conference series (1990-2006), and his position as Emeritus Professor at the University of London. Since 2003 he has been President of the International Liposome Society.